Steven Cohen’s Alto Neuroscience ANRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.7M Buy
576,375
+73,425
+15% +$2.21M 0.02% 1102
2026
Q2
$13.3M Sell
502,950
-137
-0% -$3.17K 0.01% 1114
2026
Q1
$11.3M Sell
503,087
-1,103,867
-69% -$20.5M 0.01% 1158
2025
Q4
$28.6M Buy
1,606,954
+274,517
+21% +$3.46M 0.03% 681
2025
Q3
$5.36M Buy
1,332,437
+2,682
+0.2% +$8.89K 0.01% 1043
2025
Q2
$2.93M Buy
1,329,755
+89,702
+7% +$213K 0.01% 1160
2025
Q1
$2.68M Sell
1,240,053
-452,100
-27% -$1.62M 0.01% 1150
2024
Q4
$7.16M Buy
1,692,153
+714,461
+73% +$4.46M 0.02% 827
2024
Q3
$11.2M Sell
977,692
-72,345
-7% -$885K 0.03% 608
2024
Q2
$11.2M Sell
1,050,037
-74,963
-7% -$976K 0.03% 566
2024
Q1
$17.3M Buy
+1,125,000
New +$17.6M 0.04% 497

Other funds holding ANRO

Steven Cohen's ANRO Position: Q3 2026 in Review

Steven Cohen increased its Alto Neuroscience (ANRO) stake by 15% in Q3 2026, buying an estimated $2.21M and bringing the position to 576,375 shares worth $14.7M. The position accounts for 0.02% of the portfolio, ranked #1102.

Steven Cohen first reported a position in ANRO in Q1 2024 and has held it in 11 quarters since. The position peaked at $28.6M in Q4 2025. 131 funds tracked by Wall St. Rank hold ANRO as of Q3 2026.

  • Steven Cohen held 576,375 shares of Alto Neuroscience worth $14.7M as of Q3 2026.
  • Steven Cohen bought 73,425 Alto Neuroscience shares in Q3 2026, an estimated $2.21M.
  • Alto Neuroscience made up 0.02% of Steven Cohen's portfolio in Q3 2026, its #1102 holding.
  • Steven Cohen first reported a position in Alto Neuroscience in Q1 2024 and has held it in 11 quarters since.
  • Steven Cohen's Alto Neuroscience position peaked at $28.6M in Q4 2025.
  • 131 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.